These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32552362)

  • 1. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression.
    Olfson M; Amos TB; Benson C; McRae J; Marcus SC
    J Manag Care Spec Pharm; 2018 Mar; 24(3):226-236. PubMed ID: 29485948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.
    Amos TB; Tandon N; Lefebvre P; Pilon D; Kamstra RL; Pivneva I; Greenberg PE
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
    Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
    PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Systems of Care.
    Liberman JN; Davis T; Pesa J; Chow W; Verbanac J; Heverly-Fitt S; Ruetsch C
    J Manag Care Spec Pharm; 2020 Aug; 26(8):987-995. PubMed ID: 32715964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?
    Pilon D; Sheehan JJ; Szukis H; Morrison L; Zhdanava M; Lefebvre P; Joshi K
    J Affect Disord; 2019 Aug; 255():50-59. PubMed ID: 31128505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden of treatment-resistant depression among veterans in the United States.
    Szukis H; Joshi K; Huang A; Amos TB; Wang L; Benson CJ
    Curr Med Res Opin; 2021 Aug; 37(8):1393-1401. PubMed ID: 33879005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
    Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
    J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
    Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Lefebvre P; Joshi K
    J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
    [No Abstract]   [Full Text] [Related]  

  • 14. An Evaluation of the Clinical and Economic Burden Among Older Adult Medicare-Covered Beneficiaries With Treatment-Resistant Depression.
    Benson C; Szukis H; Sheehan JJ; Alphs L; Yuce H
    Am J Geriatr Psychiatry; 2020 Mar; 28(3):350-362. PubMed ID: 31735488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the Relationship Between Depression Symptom Severity and Health Care Costs for Patients With Treatment-Resistant Depression.
    Lynch FL; Dickerson JF; O'Keeffe-Rosetti M; Chow W; Pesa J
    J Clin Psychiatry; 2022 Feb; 83(2):. PubMed ID: 35120286
    [No Abstract]   [Full Text] [Related]  

  • 16. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
    PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of home health and other healthcare delivery pathways among privately insured patients with and without treatment-resistant depression.
    Pilon D; Szukis H; Singer D; Morrison L; Sheehan JJ; Lefebvre P
    Curr Med Res Opin; 2020 May; 36(5):865-874. PubMed ID: 31985319
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
    Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
    Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Descriptive analysis of the economic burden of treatment resistance in a major depressive episode.
    Cai Q; Sheehan JJ; Wu B; Alphs L; Connolly N; Benson C
    Curr Med Res Opin; 2020 Feb; 36(2):329-335. PubMed ID: 31540559
    [No Abstract]   [Full Text] [Related]  

  • 20. Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US.
    Shah D; Allen L; Zheng W; Madhavan SS; Wei W; LeMasters TJ; Sambamoorthi U
    Pharmacoeconomics; 2021 Jun; 39(6):639-651. PubMed ID: 33904144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.